Last reviewed · How we verify
bb2121
bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA.
bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | bb2121 |
|---|---|
| Also known as | ide-cel, BMS-986395 |
| Sponsor | Celgene |
| Drug class | CAR-T cell therapy |
| Target | BCMA (B-cell maturation antigen) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
bb2121 involves engineering a patient's T cells to express a CAR that targets B-cell maturation antigen (BCMA), a surface protein highly expressed on multiple myeloma cells. Once infused back into the patient, these CAR-T cells expand and attack myeloma cells. This approach harnesses the immune system's ability to specifically recognize and eliminate cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Infections
- Fatigue
Key clinical trials
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma (PHASE2)
- A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (PHASE3)
- An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (PHASE2)
- A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant (PHASE2)
- Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
- Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (PHASE1, PHASE2)
- Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (PHASE2)
- A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bb2121 CI brief — competitive landscape report
- bb2121 updates RSS · CI watch RSS
- Celgene portfolio CI